Cutaneous metastases from bladder malignancies are rare. We report the case of a 74 year old man who underwent cysto-prostatectomy and adjuvant chemotherapy for a pT3b Nþ bladder transitional cell carcinoma. Four months later, he presented with skin disseminated pigmented lesions. Skin biopsy confirmed cutaneous metastasis from urothelial carcinoma. 
Case report
A 74 year old man was diagnosed with a non-metastatic muscle-invasive transitional cell bladder carcinoma. He underwent a cysto-prostatectomy with an ileal conduit urinary diversion. The cysto-prostatectomy specimen showed transitional cell carcinoma extending into the perivesical tissue macroscopically (Pt3b stage), with lymphatic spread in 2 lymph nodes. Cisplatin-based adjuvant chemotherapy was conducted. Four months after surgery, the patient presented with multiple disseminated pigmented and flat skin lesions (Fig. 1) .
CT scan revealed multiple subcutaneous nodules, as well as liver metastases and peritoneal carcinosis (Fig. 2) .
A skin punch biopsy of a chest lesion was performed, showing features of poorly differentiated metastatic carcinoma. Immunohistochemical diagnosis showed cytokeratin p63 positive staining, confirming urothelial origin (Fig. 3) .
Discussion
Metastasic infiltration of the skin may occur due to direct tumor invasion, hematogenous or lymphatic spread, or as a result of iatrogenic implantation of tumor cells.
1 Urinary bladder malignancies altogether account for 0.84% of cutaneous metastases. 2,3 Diagnosis requires histological confirmation by microscopic examination of a skin biopsy. 4 Prognosis of patients with bladder cancer cutaneous spread is generally poor with less than 1 year median survival. 5 In addition to cisplatine-based chemotherapy, local skin radiation therapy may be also conducted. 
